Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. (February 2020)

• Record Type: Journal Article
• Authors: Luna, Manuel Sánchez; Manzoni, Paolo; Paes, Bosco; Baraldi, Eugenio; Cossey, Veerle; Kugelman, Amir; Chawla, Rupesh; Dotta, Andrea; Rodríguez Fernández, Rosa; Resch, Bernhard; Carbonell-Estrany, Xavier
• Is Part Of: Paediatric respiratory reviews. Volume 33(2020)
• Page Start: 35
• Page End: 44
• Publication Date: 2020-02
• Subjects: RSV respiratory syncytial virus -- wGA weeks' gestational age -- WHO World Health Organization -- CLD chronic lung disease -- CHD congenital heart disease -- BPD bronchopulmonary dysplasia -- MeSH Medical Subject Headings -- GRADE Grading of Recommendations Assessment, Development and Evaluation -- ICU intensive care unit -- RSVH RSV hospitalisation -- HS haemodynamically significant -- ER emergency room -- RT-PCR reverse transcription polymerase chain reaction -- AAP American Academy of Pediatrics -- GA gestational age -- CPAP continuous positive airway pressure -- QALY quality-adjusted life year -- ICER incremental cost-effectiveness ratio -- PICU paediatric ICU -- SD standard deviation -- CF cystic fibrosis; Respiratory syncytial virus -- Evidence-based medicine -- Palivizumab -- Lower respiratory tract infection -- Neonatal lung disease; Pediatric respiratory diseases -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory Therapy -- Periodicals; Child -- Periodicals; Appareil respiratoire -- Infections, chez l'enfant -- Périodiques; Appareil respiratoire -- Maladies, chez l'enfant -- Périodiques; 618.922
• DOI: 10.1016/j.prrv.2018.12.001
• Languages: English
• ISSNs: 1526-0542

Abstract

Abstract: Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32–35 wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV.